Good clinical trial results are always welcomed. Earlier this week, drug delivery expert Alkermes
Details were light on the results of the study that prompted Alkermes to continue development of ALKS 29. The company did note that results were statistically significant across a range of efficacy endpoints, including percent of days abstinent and decrease in drinking compared to placebo in combination with psychosocial therapy.
Alkermes successfully shepherded another alcohol dependence treatment, named Vivitrol, through the regulatory process last year. Sales of the injectable medication by partner Cephalon
Although there are other oral medications on the market already, another oral treatment for alcoholism such as ALKS 29 could do better in the market than Vivitrol. Such a treatment could address some of the problems that have hampered the use of Vivitrol, like its high cost and the fact that it must be administered via injection.
Despite this early clinical-stage success, Alkermes' future will clearly be determined by how well its two late-stage diabetes compounds, under development with Eli Lilly
Looking for more Foolish drug-stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations, as well as get access to our message boards and exclusive content, with a 30-day free trial.